Table 3 Association of clinical, pathological and genotypic parameters with radiological response at 4th month of letrozole administration.
Parameters | Responders (%) | Non-responders (%) | p |
|---|---|---|---|
Age (years) | Â | Â | Â |
   ≤ 78.3 | 19 (54.3) | 29 (48.3) | 0.576 |
   > 78.3 | 16 (45.7) | 31 (51.7) |  |
Histological diagnosis | Â | Â | Â |
   IDC | 25 (71.4) | 42 (70.0) | 0.843 |
   ILC | 5 (14.3) | 11 (18.3) |  |
   Others | 5 (14.3) | 7 (7.4) |  |
Histological grade | Â | Â | Â |
   I | 13 (61.9) | 16 (51.6) | 0.606 |
   II | 6 (28.6) | 13 (41.9) |  |
   III | 2 (9.5) | 2 (6.5) |  |
Tumor size (T) | Â | Â | Â |
   T2 | 31 (88.6) | 45 (75.0) | 0.111 |
   T3-T4 | 4 (11.4) | 15 (25.0) |  |
Lymph node involvement (N) | Â | Â | Â |
   NO | 28 (80.0) | 48 (80.0) | 1.000 |
   N1-2 | 7 (20.0) | 12 (20.0) |  |
Stage | Â | Â | 0.546 |
   IIa | 26 (74.3) | 39 (65.5) |  |
   IIb | 7 (20.0) | 13 (21.7) |  |
   IIIa-IIIb | 2 (5.7) | 8 (13.3) |  |
ER | Â | Â | Â |
   ≤ 40% | 3 (8.6) | 10 (16.7) | 0.268 |
   > 40% | 32 (91.4) | 50 (83.3) |  |
PgR | Â | Â | Â |
   ≤ 40% | 15 (42.9) | 31 (51.7) | 0.407 |
   > 40% | 20 (57.1) | 29 (48.3) |  |
HR | Â | Â | Â |
   ≤ 40% | 2 (5.7) | 8 (13.3) | 0.243 |
   > 40% | 33 (94.3) | 52 (86.7) |  |
HER2 | Â | Â | Â |
   0, + | 21 (60.0) | 42 (70.0) | 0.320 |
   ++, +++ | 14 (40.0) | 18 (30.0) |  |
Ki67 | Â | Â | Â |
   Negative | 15 (55.6) | 25 (55.6) | 1.000 |
   Positive | 12 (44.4) | 20 (44.4) |  |
rs10046 | Â | Â | Â |
   GG | 6 (17.1) | 9 (15.0) | 0.782 |
   AG/AA | 29 (82.9) | 15 (85.0) |  |
rs4646 | Â | Â | Â |
   CC | 26 (74.3) | 31 (51.7) | 0.030 |
   AC/AA | 9 (25.7) | 29 (48.3) |  |